Avai Bio (AVAI) Cash from Financing Activities (2018 - 2025)

Avai Bio has disclosed Cash from Financing Activities across 8 years of filings, most recently posting $305534.0 for Q4 2025.

• Cash from Financing Activities for Q4 2025 came in at $305534.0, up 125.24% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.2 million (up 7.38% YoY), and the FY2025 annual result was $1.2 million, down 9.0% from the prior year.
• Cash from Financing Activities came in at $305534.0 for Q4 2025 at Avai Bio, down from $453480.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $1.0 million in Q1 2022 to a low of -$722791.0 in Q4 2021.
• The 5-year median for Cash from Financing Activities is $149030.0 (2023), against an average of $207736.7.
• Across the five-year window, Cash from Financing Activities plunged 1464.89% in 2021 and jumped 6644.1% in 2022, its largest moves.
• Avai Bio's Cash from Financing Activities stood at -$722791.0 in 2021, then surged by 97.56% to -$17665.0 in 2022, then soared by 4091.42% to $705085.0 in 2023, then plunged by 80.76% to $135651.0 in 2024, then jumped by 125.24% to $305534.0 in 2025.
• The last three Cash from Financing Activities figures came in at $305534.0 (Q4 2025), $453480.0 (Q3 2025), and $169352.0 (Q2 2025), per Business Quant data.